ALL INDIA INSTITUTE OF MEDICAL SCIENCE

• Indigenously developed HPV test kits for cervical cancer screening were launched in Delhi, targeting the seven to eight most common cancer-causing HPV types specific to India's population. • The RTPCR-based diagnostic kits, validated through collaborative research led by AIIMS Delhi, offer a cost-effective alternative to traditional Pap smears and HPV DNA tests for national cancer screening programs. • With cervical cancer being the second most common cancer among Indian women and accounting for 25% of global mortality, these kits align with WHO's recommendation for HPV testing as the preferred screening method.

Immuneel Therapeutics has launched Qartemi, India's first CAR T-cell therapy for treating adult B-cell Non-Hodgkin Lymphoma (B-NHL).